"We are seeking to deliver these ASO cargoes into the back of the eye to address diseases occurring in the retina. CPP-mediated ASO delivery holds a number of important advantages over other alternative therapeutic approaches (including gene therapy) in this specific environment – notably, an even distribution of drug throughout the affected tissue and correction of protein levels within normal parameters, amongst others."
Refer to Hottod's post here...
https://hotcopper.com.au/threads/ann-flagship-program-successful-animal-models.4670547/page-11?post_id=37733533
Then have a read of page two and three of the company announcement dated 12/03/19 below.
https://hotcopper.com.au/threads/ann-flagship-program-successful-animal-models.4670547/?post_id=37728869
Tony
Ann: March 2019 Quarterly Operational Update and App4C, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.015(1.16%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.28 | $9.623K | 7.405K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1993 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 14649 | 3 |
View Market Depth
| Last trade - 10.00am 28/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |